BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency
about
Opportunities for immunotherapy in microsatellite instable colorectal cancerCarcinogenesis and microsatellite instability: the interrelationship between genetics and epigeneticsProliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations.Optimization of a pentaplex panel for MSI analysis without control DNA in a Brazilian population: correlation with ancestry markers.BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome.Defining new criteria for selection of cell-based intestinal models using publicly available databases.Causes and consequences of microsatellite instability in gastric carcinogenesis.High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancerDecreased tumor progression and invasion by a novel anti-cell motility target for human colorectal carcinoma cells.BRAFV600E mutation analysis in patients with metastatic colorectal cancer (mCRC) in daily clinical practice: correlations with clinical characteristics, and its impact on patients' outcome.ERK/pERK expression and B-raf mutations in colon adenocarcinomas: correlation with clinicopathological characteristics.Comparative expression patterns and diagnostic efficacies of SR splicing factors and HNRNPA1 in gastric and colorectal cancerK-Ras and B-Raf oncogenes inhibit colon epithelial polarity establishment through up-regulation of c-myc.Targeting inhibition of extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) suppresses growth and angiogenesis of gastric cancer.KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: results from a large international multicentre studyBRAF V600E mutation in metastatic colorectal cancer: Methods of detection and correlation with clinical and pathologic features.The homeobox gene MEIS1 is methylated in BRAF (p.V600E) mutated colon tumors.Oncogenic mutations and microsatellite instability phenotype predict specific anatomical subsite in colorectal cancer patients.Response to MLN8237 in pancreatic cancer is not dependent on RalA phosphorylation.On target? Strategies and progress in the development of therapies for colorectal cancer targeted against WNT signalling.Anti-HER agents in gastric cancer: from bench to bedside.Lynch syndrome diagnostics: decision-making process for germ-line testing.Biomarkers for gastric cancer: prognostic, predictive or targets of therapy?Evolving role of gene expression signatures as biomarkers in early-stage colon cancer.Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies.Microsatellite instability: an update.Molecular classification of gastric adenocarcinoma: translating new insights from the cancer genome atlas research network.Aberrant methylation of hMLH1 and p16INK4a in Tunisian patients with sporadic colorectal adenocarcinoma.Hypericum androsaemum water extract inhibits proliferation in human colorectal cancer cells through effects on MAP kinases and PI3K/Akt pathway.Braf, Kras and Helicobacter pylori epigenetic changes-associated chronic gastritis in Egyptian patients with and without gastric cancer.Salvia fruticosa, Salvia officinalis, and rosmarinic acid induce apoptosis and inhibit proliferation of human colorectal cell lines: the role in MAPK/ERK pathway.BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations.BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab.KRAS Mutation in Gastric Cancer and Prognostication Associated with Microsatellite Instability Status.KRAS mutations in microsatellite instable gastric tumours: impact of targeted treatment and intratumoural heterogeneity.Unmasking the role of KRAS and BRAF pathways in MSI colorectal tumors.Comprehensive characterization of HNPCC-related colorectal cancers reveals striking molecular features in families with no germline mismatch repair gene mutations.BRAF V600 co-testing in thyroid FNA cytology: short-term experience in a large cancer centre in the UK.KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression
P2860
Q28066110-7B33FBEF-2B93-468F-A459-603EDFDD3A03Q28253670-D53174AB-4B4B-4952-84B1-33898F7C4950Q33514138-F0060DA1-A358-4397-99F8-43366D2DC47BQ33765195-3589C288-658F-47EA-816E-63B42D2A3833Q33906044-73CAFD7F-CD28-449D-8EF8-3ABD06B6004FQ34314896-6C6C9372-6ABB-4CD5-BD3B-24B92D62F6C8Q34589660-F843CFEB-5D37-425E-ACBC-34FA815480ECQ34645477-4680CDC7-19C1-4EE4-A0C5-114B141E0FF7Q34766871-6FD9B049-A442-4304-911E-B69F6E00C5F8Q35075820-9371A261-4C96-443A-B3E1-7FA2930BBE34Q35873526-0AED7366-6475-42E2-B2AE-F172F30E8525Q36047336-9128F155-CBA7-47FC-AA8D-20F5A5F92CC8Q36135264-1A3BBEAA-6308-4AE3-BEAB-37D2DAC27E1BQ36280358-4167052A-F9D8-4275-96D2-DE9A6A64DB40Q36775338-9F7B8A22-A5BE-430F-9E14-036DC8F2551FQ37216950-39966242-0156-4BE3-AA0E-9FF5B671517CQ37288532-3C969EC0-7688-4BD7-8F52-60223F75EC79Q37316996-3E7BABC5-8812-4262-8CD1-8AA9A5ED0B7EQ37542817-2F5ADE87-AF1C-4236-9555-0803F08E2D2DQ37656544-BF9605D5-59CD-40A4-A03C-A47AEF785DEEQ37885725-40441B67-C0FA-452E-A113-7D59F19DE6A3Q38000941-DE930C06-733C-4913-AC84-594696822885Q38184380-669B97B1-C1E0-488D-930E-DF2CB662C7A5Q38225744-C85B9E2A-04EE-49EC-94DD-89511A799DDDQ38239612-A308F7EF-ED5D-4BE5-8F6F-1D730A335880Q38363519-C0D7B2AE-8486-4C90-8231-A5DF6C3E635DQ38392332-5297304C-77C9-434D-98FD-120EC6352A77Q39250757-0E54F556-0A36-4B98-AB70-AF56706FD63FQ39346470-096FF652-7FA0-460D-BF39-BFE604495B93Q39418193-767D76A2-819D-434E-AC20-2FCE22516AD0Q39786082-C07A7C65-111B-4709-B4F8-709FA54FD18CQ40031893-D1A30652-EFDD-4AE6-950D-C7E41F0FBB31Q42947711-C49FDE48-E7FF-43B0-8D7B-8D9896C51678Q46390622-14C373E5-640C-4123-A844-27AF881D2E32Q47586172-56AE8229-87F6-4B51-A3CA-BE65D048473DQ48140493-E2942268-BD71-4B7E-B7D4-8BD472FEF379Q51827376-77B0D440-4F57-450B-98A4-15AFE7F13CF8Q53361302-121108B4-9CCD-45D1-8BB7-38A6800B3867Q54349226-C91A1F10-BFEA-4D55-B745-76073D2D5AF4Q58966086-A272C22C-B424-4F94-B847-CC2D96EF37EE
P2860
BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency
description
im Dezember 2003 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 December 2003
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в грудні 2003
@uk
name
BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency
@en
BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency
@nl
type
label
BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency
@en
BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency
@nl
prefLabel
BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency
@en
BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency
@nl
P2093
P50
P356
P1433
P1476
BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency
@en
P2093
Alex Duval
Carla Oliveira
Caroline Brennetot
Eloi Espín
Enric Domingo
Hiroyuki Yamamoto
Richard Hamelin
P2888
P304
P356
10.1038/SJ.ONC.1207061
P407
P577
2003-12-01T00:00:00Z